The identification and understanding of the molecular network of cancer stem cells (CSCs) have had a profound impact on our view of carcinogenesis and treatment strategy. Unfortunately, a major problem is that serial passages of CSCs from clinical solid tumor specimens currently are not available in any lab, and thus, reported data are difficult to confirm and intensively interrogated. Here, we have generated two tumor tissue-derived breast CSC (BCSC) lines that showed prolonged maintenance over 20 serial passages in vitro, while retaining their tumor-initiating biological properties. We then deciphered the intrinsic mechanism using analyses of mRNA expression array profiles. It has been determined that pro-opiomelanocortin (POMC) is closely related with protein phosphorylation mediated by G-protein-coupled estrogen receptor (GPER) in BCSC. Following, knockdown of POMC inhibits properties of mammosphere formation, CD44
cancers. They also play an important role in both tumorigenesis and therapeutics. 3, 4 Moreover, CSCs are promising cell lines for cancer therapy, due to their wide differentiation potentials and resistant to most conventional therapies. 5 Only a small fraction of the infused CSCs is able to engraft into the tissue and successfully differentiate into tumor tissue. 6, 7 Along with the development of CSCs investigation, series of specific tumor-initiating properties for breast CSCs (BCSC) identification could be defined. 8, 9 BCSC possess the properties of CD44 1 CD24 2 Lin 2/l 8 w phenotype, 10 ALDH1 1 marker, 11 selfrenewal, 12 mammosphere formation, 12, 13 tumorigenic activity 14 and epithelial-mesenchymal transition. 15 Recently, CSCs have been isolated from several human tumors, to the best of our knowledge, but there have been no reports in the literature regarding permanent maintenance of CSCs lines derived from clinical tumor specimens; therefore, the reported mechanisms within CSCs are difficult to reproduce and have been intensively interrogated. 9 However, long-term maintenance of BCSC could be a great benefit for enabling research progress in breast cancer.
In this study, we aimed to identify in vitro long-termcultured BCSC derived from tumor tissue. We further sought to an insight into the possible molecular mechanism, which may regulate tumor-initiating properties of BCSC and can be applied to treatments for breast cancer.
Material and Methods

Patients and animal studies
Informed consent was obtained from all patients. All animal experiments and related studies were approved by the research ethics committee of Sun Yat-sen University Cancer Center (SYSUCC).
Isolation and passage of BCSC lineages
BCSC were maintained as spheres in ultralow attachment flasks in serum-free DMEM-F12 and supplemented with 10 ng/mL basic fibroblast growth factor (BFGF), 20 ng/mL epidermal growth factor (EGF), 2% B27, 5 mg/mL insulin and 10,000 IU/mL penicillinstreptomycin. See Supplemental Experimental Procedures in Supporting Information for details on data processing.
Short tandem repeat (STR) profiling
We used the QIAamp DNA Mini Kit (20-30 ng/sample) to extract genomic DNA from BCSC. STR-based multiplex PCR was carried out with the PowerPlex16 HS System according to the manufacturer's protocol.
Patients, tissues, tissue microarray construction (TMA) and immunohistochemistry (IHC)
A total of 134 female patients who were hospitalized in SYSUCC from October 2001 to September 2006 were enrolled in our cohort. A complete patient follow-up was performed, and endpoint of this follow-up was August 2015. Expression data were obtained from 217 fresh-frozen resected breast specimens consisting of 134 tumor tissues and 83 adjacent normal breast tissues. The primary antibodies included POMC (1: 200), GPER (1:250), p53 (1:50), ER (1:50), PR (1:500), HER2 (1:50), Ki-67 (1:100), E-Cadherin (1:100), p63 (1:200), a-SMA (1:200), Muc1 (1:50), and EGFR (1:100). In addition, staining procedures were performed by using Bench Mark XT automated IHC/ISH slide staining system.
Preparation of adenovirus vectors
The recombinant adenovirus vectors containing POMC-Ad (addition of POMC) and POMC-KD (knockdown of POMC) were generated as previously described. 16, 17 Western blot analysis Protein extracts of BCSC (10 mg protein) were detached by 10% SDS-PAGE and electrophoretically transferred to polyvinylidene difluoride (PVDF) membrane. Following, antibodies were assayed. Antibodies of AKT1, AKT2, GSK3b, phospho-AKT1, phospho-AKT2 and phospho-GSK3b were purchased from Cell Signaling Technology. We performed GAPDH or b-actin as internal control. Signals were visualized using the Supersignal West Pico ECL chemiluminescence detection kit and Kodak X-ray film. Further details were available in Supplemental Experimental Procedures (Supporting Information).
Flow cytometry
Fluorescence-activated cell sorting (FACS) was performed to determine the CD44
1
CD24
2 subpopulation and proportion of Lin or ALDH1 in BCSC by using CD44 1 , CD24 2 , Lin-PE and ALDH1-PE antibodies. Differentiation capabilities of BCSC were further analyzed by flow cytometry. Briefly, BCSC (5 3 10 7 cells) were transfected with Muc1-PE or a-SMA-PE for 48 hr. Positive GFP-labeled cells were purified by FACS. Then, isolated cells were contained with 2 mL DAPI (10 mg/mL) for 5 min. We used CellQuest software to analyze the data.
What's new?
Cancer stem cells (CSCs), which serve functions in tumor development and drug resistance, are of tremendous value in cancer research. Their long-term culture, however, has proven difficult. Here, two tumor tissue-derived breast cancer stem cell (BCSC) lines were successfully established and maintained in culture for more than 20 serial passages, without loss of original properties. Long-term culture enabled detailed molecular investigation, with mRNA expression analyses revealing a role for proopiomelanocortin (POMC) in BCSC. Knockdown of POMC attenuated tumor-initiating properties and AKT2/GSK3b phosphorylation in cells and, in vivo, inhibited BCSC proliferation. POMC was linked to poor prognosis in breast cancer patients.
Clonogenicity assays in soft agarose
Clonal expansion ability of BCSC was analyzed by clonogenicity assays in soft agarose. Briefly, BCSC were transfected with control (Ctrl, empty vector), POMC-KD and POMCAd, respectively. Next, 2% solidified agar was paved as base agar in 6-well. BCSC were seeded at 3 3 10 3 cells per well coated with a thin layer of 1% soft agarose. The experiment was terminated at Day 21, and wells were Giemsa-stained. Spheres with 50 mm or greater in diameter were determined. We performed all experiments for three times.
Establishment of serial passages of green fluorescent protein (GFP)-labeled BCSC lines BCSC were transfected with pcDNA3.1-EGFP-NEO and selected with G418. Initially, GFP-labeled BCSC were collected, identified and maintained. Following, G418-resistant clones were designated as GFP-labeled BCSC.
Clonal pair-cell analyses
In brief, BCSC (5 3 10 6 cells) were transfected with plasmid containing GFP for 24 hr, GFP-labeled POMC-KD plasmid for 48 hr, and stained with 2 lL DAPI (10 mg/mL) for 5 min, respectively. Next, BCSC were collected, washed twice with icecold PBS and counterstained with anti-CD44-PE (1:200) for 30 min. Following, images were acquired by an inverted epifluorescence microscope system and further analyzed by digital confocus. 8 We performed Image of Live Cell Imaging Confocal Scanner System (CV1000) to maintain and photograph these cells. All analyses were repeated for five times.
Establishment of serial passages of luciferase-labeled BCSC lines
Protocol of serial passages of cell lines expressing firefly luciferase was previously described. 18 Briefly, BCSC expressing GFP were transduced with pEF1a-Luc-Neo, and further selected with G418. Next, G418-resistant clones, designated as Luciferaselabeled BCSC, were collected, identified and maintained.
Tumor transplantation experiments
To test tumorigenesis abilities of BCSCs in vivo, we established orthotopic xenograft models of BCSC and unsorted parent cells coming from clinical samples. Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice were raised in a specific pathogen-free environment according to the institutional policy. Tumor progression was evaluated daily using the In Vivo Imaging System (IVIS system) equipped with Living Imaging software. The protocols were generated as previously described. [18] [19] [20] Details were available in Supplemental Experimental Procedures (Supporting Information).
Microarray analyses of mRNA expression profiles
Microarrays were determined with Affymetrix Genechip scanner 3000 controlled by Affymetrix Genechip Command Console software. We conducted microarray experiments according to the manufacturer's instructions (Invitrogen Life Technologies, Capital Biochip Corporation). See also Supplemental Experimental Procedures (Supporting Information).
Statistical analyses
All results were obtained from at least three independent experiments and were expressed as the mean 6 standard deviation. For comparisons, Student's t test (two-tailed), Wilcoxon signed-rank test, Pearson v 2 test, Pearson correlation analysis, Log-rank test, Fisher's exact test and nonparametric Mann-Whitney U test were performed as indicated. Survival rates were analyzed by log-rank test using SPSS 13.0 software (SPSS, Chicago, IL, USA). The significance level was set at p < 0.05.
Results
Here we successfully purified and maintained two BCSC lines (BCSC1/XM322 and BCSC2/XM607) derived from 2 (out of 22) clinical samples with surgically resected breast cancer (Supporting Information, Table S1 ). Both BCSC lines sustained > 20 passages for > 4 years. They were characterized by mammospheres formation, self-renewal capacity (Fig. 1a) , CD44 (Fig. 1b) , pluripotency under differentiation culture (Muc 1 and a-SMA) (Fig. 1c) and clonogenicity in soft agarose (Fig. 1d) . Furthermore, BCSC were genotyped for up to 16 short tandem repeat (STR) markers. BCSC held the genetic phenotypes of human (D3S1358, TH01, D21S11, Penta E, D5S818, D13S317, D7S820, D16S539, CSF1PO, Penta D, vWA, D8S1179, TPOX and FGA, Fig. 1e ). All together, we initially found that BCSC were characterized by the capacities for self-renewal, unlimited proliferation and multipotential differentiation in vitro.
Besides having the inherent properties of stem cells in vitro from 5 th passage to 20 th passage, both cell lines kept the characteristics of CSCs in vivo. Establishing mammary tumors in NOD/SCID mice only needs 1 3 10 3 CD24 2
CD44
1 BCSC injection (Supporting Information, Table S2 ). A similar tumor-forming ability has been found from the ensuing generation of NOD/SCID mouse BCSC (Fig. 1f) . Both pathology types of the two initiating tumor tissues were invasive ductal carcinoma. Similarly, each differentiated tumors of BCSC-bearing mice remained invasive ductal carcinoma. In addition, to determine the differentiation capabilities of BCSC, we performed IHC expressions of 20 th passage BCSC-bearing tumors comparing with their primary cells-bearing tumors. Representative images (Fig. 1g ) and statistical results (Supporting Information, Table S3 ) of IHC expressions (p53, ER, PR, HER2, Ki-67, E-Cadherin, p63, a-SMA, Muc1 and EGFR) were presented. From the results of IHC expressions, we indicated that 20 th passage BCSC maintained their innate abilities of pluripotent differentiation to breast tumor cells.
To better investigate the properties of BCSC, we explored the potential application of 20 th generation of two BCSC via microarray analyses of mRNA expression profiling. Next, the significant genes were submitted to the DAVID (Database for Annotation, Visualization and Integrated Discovery) bioinformatics free online resource tool (http://david.abcc.ncifcrf.gov/). We found that protein phosphorylation was the most important function-related term in BCSC genes (Supporting Information, Table S4 ). Previously, G1 and G15 have been reported that they contribute to phosphorylation and dephosphorylation of proteins in cells, respectively. 21 G1 acts as a selective agonist of GPER (also known as G-protein-coupled receptor GPR30); conversely, G15 is an antagonist of estrogen signaling through GPER. 21 Following, BCSC were treated with G1 and G15, and gene lists of interest (all genes up-or downregulated more than twofold, p < 0.05) were further analyzed in the DAVID database. Here, the resulting data indicated that pro-opiomelanocortin (POMC) is the most important gene, which is involving in phosphoprotein of BCSC ( Fig. 2a and Supporting Information, Table S5 ). Combining properties of G1 and G15 to GPER, we summarized that POMC was closely related with protein phosphorylation mediated by GPER in BCSC. In addition, we found that POMC expression in BCSC was higher than that in their primary breast tumor cells; whereas protein expression of ACTH (adrenocorticotropic hormone) in BCSC was lower than their primary tumor cells (Fig. 2b) .
POMC mRNA is the precursor of ACTH, a-MSH (a-melanocyte-stimulating hormone) and b-END (b-endorphin). 22, 23 To explore which POMC-derived peptides potentially mediating the tumor-initiating biological properties in BCSC, we determined interference effects of these peptides on their tumorinitiating properties. Preliminarily, we constructed regulators of ACTH, a-MSH and b-END ( Supporting Information, Figs.  1a21c) . Discouragingly, regulations of ACTH, a-MSH and b-END did not alter the proportion of CD44 1 CD24 2 in BCSC ( Supporting Information, Figs. 2a22c) . The data showed that regulations of the peptides had no significant alteration on proportion of CD44 1 CD24 2 in BCSC. However, we found that addition of exogenous POMC (POMC-Ad) upregulated expressions of CD44 and POMC in BCSC; conversely, knockdown of POMC (POMC-KD) downregulated expression of these proteins (Fig. 2c) . Meanwhile, neither POMC-Ad nor POMC-KD altered expressions of ACTH, a-MSH and b-END in BCSC (Fig. 2c) indicated that BC released more secretions of POMC, ACTH, a-MSH and b-END into supernatants than BCSC ( Supporting  Information, Figs. 3a23d) . Meanwhile, regulation of POMC did not significantly change the supernatant levels of POMC, ACTH, a-MSH and b-END in BCSC culture (Supporting Information, Figs. 3a23d) . The aforementioned findings were exciting because they hinted that POMC rather than ACTH, a-MSH or b-END, mediating the regulation of tumor-initiating properties in BCSC.
Then, we evaluated the effect of POMC interference on tumor-initiating properties of BCSC. Interestingly, POMC-KD reduced the proportion of CD44 1 CD24 2 in BCSC;
whereas POMC-Ad increased the population of these cells (Fig. 2d) . Following, we found that POMC-Ad promoted mammosphere formation of BCSC, while POMC-KD inhibited this ability of CSCs significantly (Fig. 2e) . Furthermore, sphere-formation assay within soft agarose has been performed to evaluate the activity of BCSC. Clonogenic assays found that POMC-KD decreased clonogenicity ability within soft agarose of BCSC; however, POMC-Ad increased this capability (Fig. 1f) . With a goal of evaluating the effect of POMC-KD on CD44 expression in BCSC, we constructed a POMC-KD-GFP nanoparticle to perform clonal pair-cell assays. Encouragingly, clonal pair-cell assays demonstrated that POMC-KD suppressed CD44 expression significantly in BCSC (Fig. 2g) . In summary, we found that POMC-KD significantly eliminated the tumor-initiating properties of BCSC. As AKT and GSK were involved in protein phosphorylation induced by G1, we evaluated whether POMC intervene affected expressions of AKT1, AKT2 and GSK3b in BCSC (Fig. 2h) . POMC-Ad and G1 stimulated phosphorylation expressions of AKT2 and GSK3b; conversely, POMC-KD and G15 inhibited these expressions. Importantly, the effect of protein dephosphorylation on BCSC by G15 could be reversed by POMC-Ad. Although G15 attenuated expression of AKT1 phosphorylation, p-AKT1 expression did not alter significantly with other treatments. The above results indicated that POMC-KD played a role in attenuating phosphorylation of AKT2 and GSK3b in BCSC.
To further confirm the therapeutic effect of POMC on BCSC in vivo, we established and maintained BCSC lines expressing firefly luciferase. Imaging revealed that POMC-KD led to a significant decrease in bioluminescent signal of BCSC-bearing tumors (Figs. 2i and 2j) . However, there were no significant associations among groups of control, G1 and G15. Moreover, study group of POMC-KD prolonged mouse survival even more effectively than the POMC-Ad group (Fig. 2k) . In addition, it has been indicated that body weights for all participating nude mice did not change significantly ( Supporting Information, Fig. 4) , suggesting that the POMC interference on body metabolism was well tolerated. Thus, POMC-KD inhibited cell proliferation of BCSC in vivo experiments.
Given the striking treatment effect of POMC regulation on BCSC, we then measured whether there was an association between POMC expression and clinicopathological features in breast cancer. To answer this question, we retrospectively analyzed POMC expression and other clinicopathological data from 134 patients with surgically resected breast cancer (Supporting Information, Table S6 ). There has been shown the representative examples of breast cancer tissues immunostained with POMC (Fig. 3a, upper panel) and GPER (Fig. 3a, middle  panel) , as well as immunohistochemical expression of POMC in their adjacent healthy normal breast tissues (NBT) (Fig. 3a,  lower panel) . POMC expression was significantly related with pathological staging and GPER expression, but was not apparently associated with their breast cancer subtypes (ER status, PR status, HER2 status or presence of triple-negative breast cancer) (Supporting Information, Table S7 ). More importantly, POMC expression was positively correlated to the GPER status (OR 5 9.731). Additionally, we examined POMC expression in 83 adjacent healthy NBT. Further investigation indicated that POMC positive expression in NBT was lower than stage III breast cancer, which was less than stage III (Supporting Information, Table S8 ). Collectively, our data of IHC provided evidences that POMC was frequently upregulated in advanced breast tumors.
To evaluate the potential clinical prognostic significance of POMC in breast cancer, we performed univariate (Supporting Information, Table S9 ) and multivariate (Supporting Information, Table S10 ) survival analyses in this group of patients. After adjustment for multifactors, both disease-free survival (DFS) and overall survival (OS) were significantly affected by POMC expression (Fig. 3b) , pathological staging (Fig. 3c ), p53 status (Fig. 3d ) and triple-negative breast cancer status (Fig. 3e) . GPER positive expression seemed to be an unfavorable factor for patients with breast cancer; however, this association was only on the borderline (Fig. 3f) . In our study, POMC expression was an independent poor prognostic marker in patients with surgically resected breast cancer.
Discussion
To our knowledge, for the first time, we have successfully established two long-term-cultured BCSC from clinical specimens. It is crucial for long-term maintenance of BCSC to select out proper culture medium, avoid fungi infection and reduce unnecessary intense shock. In addition, our results indicated that POMC-KD inhibits nature of mammosphere formation, CD44
1 CD24 2 population, CD44 expression and clonogenicity ability in BCSC. We further found that POMC-KD plays a role in attenuating phosphorylation of AKT2 and GSK3b in BCSC. In vivo mice experiments demonstrated that POMC interference regulates proliferation of BCSCbearing tumors. In a word, POMC is a novel therapeutic target for BCSC both in vitro and in vivo.
Transcription and translation of the POMC gene have been detected in skin, bone, pituitary gland and most peripheral tissues. 22 Here we found that POMC expression was upregulated, but ACTH expression was downregulated in BCSC in comparison with their primary breast tumor cells. Conversely, results from analyses of supernatant levels showed that BCSC released slighter secretions of POMC, ACTH, a-MSH and b-END than their primary breast cancer cells. Moreover, POMC interferences did not significantly alter the supernatant levels of these secretions in BCSC maintenance. Accordingly, higher POMC expression and lower secretions of POMC and POMC-derived peptides may reveal the status of inert and hypometabolism in BCSC.
More recently, evidences existed that ACTH has an increase of the proliferative index and differentiation of stemlike cells. 24 Meanwhile, recent trials showed that ACTHcontaining medium may contribute to the establishment of stem cell lines. 25 However, our results indicated that only POMC rather than ACTH, a-MSH or b-END can regulate CD44 expression in BCSC. Further investigations confirmed that POMC mediates CD44 expression, CD44
1 CD24 2 proportion, mammosphere formation, clonogenicity ability and augmenting effects on proliferation in BCSC. Thus, we demonstrated that POMC mediating in the regulation of tumorinitiating properties in BCSC.
Noticeably, there is no difference on tumor growth among study groups of control, G1 and G15. The following reasons might be the plausible causes for these situations. It has been known that the compound of G1 or G15 binds to GPER but not ERa or ERb. 21 Furthermore, stimulation of GPER can initiate numerous downstream multiple pathways, including numerous counteract signaling pathways, to product complicated or even contradictory effects. 26 Moreover, our data of the positive correlation between expressions of POMC and GPER suggested that POMC may be the downstream of GPER signaling. Therefore, POMC, rather than GPER, acts as the novel therapeutic target for BCSC.
Previous investigations indicated that POMC neuron mainly involving in the process of energy metabolism, [27] [28] [29] obesity regulation, 30, 31 nicotinic-induced decreases in food intake 32 and browning of white fat. 16 Most mechanism researches demonstrated that POMC neurons play an essential regulator for leptin, 16, 29, 30 insulin, 16, 27 MC4R, 32 CpG island, 31 glucagon-like peptides 27 and mitofusin 2. 28 This study showed that POMC activates the phosphorylation of AKT2 and GSK3b in BCSC. Given the central role of AKT2/ GSK3b in glucose homeostasis, 33 our results revealed a key regulatory role of POMC in energy metabolism of BCSC. Moreover, recent studies reported that EGFR plays a fundamental role in tumor-initiating properties of CSCs, 34, 35 and that inhibition of EGFR kinase activity in canine tumor cell cultures suppressed 80% of POMC expression and 75% of ACTH secretion. 36 So, the aforementioned results suggested that both POMC and ACTH receptor signals maybe downstream of EGFR in CSCs. Recently, some investigations found that POMC expression are significantly associated with docetaxel-induced anorexia, 37 DNA methylation, 38 and morbidity risk in breast cancer. 39 Previously, Stovold et al. found that POMC expression predicts poor survival and liver metastases in patients with small-cell lung cancer. 40 Similar results were reported by
Hao et al. They found that positive expression of POMC is a novel, independent poor prognostic marker in patients with non-small-cell lung cancer. 41 Here, we indicated that POMC expression is frequently upregulated in human breast cancer, and POMC positivity expression correlated with a poor prognosis. These outcomes suggested that POMC serves on a crucial role of the novel phenotype in patients with breast cancer.
In conclusion, to the best of our knowledge, for the first time, we established long-term maintenance of BCSC from clinical specimens; this achievement is very important to an insight into the accurate molecular mechanisms of BCSC and, ultimately, it may be contributed to the eradication of breast cancer. We further indicated that POMC acts as a potential therapeutic target and prognostic marker for future treatment of BCSC.
